RPCEC00000085已完成4 期
Effectiveness and Safety of use ior LeukoCIM as prophylaxis and treatment of Neutropenia in patients with HIV/AIDS.
Center of Molecular Inmunology(CIM)0 个研究点开始时间: 2009年8月20日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Treatment
入排标准
- 年龄范围
- 18 years 至 none（—）
- 性别
- All
入选标准
- •1.HIV/AIDS patients who are or not associated to an opportunistic malignant disease and who meet the diagnostic criteria. 2.Patients who signed their consent in order to participate in the study. 3.Patients older than 18 years. 4.Patients of both sexes.
排除标准
- •1.Patients with known hypersensitivity to E.Coli cell products or other preparations of rG-CSF. 2.Pregnant patients or breastfeeding.
研究者
相似试验
尚未招募
不适用
A prospective study of the clinical utility of immunocytochemistry in liquid-based cytology for pancreatic tumorsPancreatic tumorsJPRN-UMIN000020575Okayama University Hospital30
已完成
4 期
Effectiveness and Safety of ior EPOCIM in patients with Chronic Renal Failure on dialysis methods.Chronic Renal Insufficiency.RPCEC00000082Center of Molecular Immunology(CIM)621
招募中
不适用
Investigation of clinical efficacy and safety of intramuscular administration of autologous total IgG therapy in patients with chronic urticariaDiseases of the skin and subcutaneous tissueKCT0006814Ajou University Hospital24
已完成
3 期
Effectiveness and safety of ior EPOCIM in anemia in premature infant.Anemia of preterm newbornRPCEC00000088Center of Molecular Immunology(CIM)72
尚未招募
4 期
Study of efficacy and side effects of imeglimin as an antidiabetic agent as single drug or as an add on drugCTRI/2024/04/065835Abhinav Garg